Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives

1.•

Mottaran A, Ercolino A, Bianchi L, Piazza P, Manes F, Amirhassankhani S, et al. Twenty years’ experience in retroperitoneal lymph node dissection for testicular cancer in a tertiary referral center. Medicina (B Aires). 2023;59(1) https://doi.org/10.3390/MEDICINA59010133. This recent article details a series of retroperitoneal lymph node dissections (RPLNDs) conducted between 2000 and 2019 for testicular cancer (TC) at a tertiary referral center. It prospectively evaluates surgical and perioperative outcomes, complications, recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS). Multidisciplinary Digital Publishing Institute (MDPI).

2.

Schwen ZR, Gupta M, Pierorazio PM. A review of outcomes and technique for the robotic-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer. Adv Urol. Hindawi Limited; 2018;2018. https://doi.org/10.1155/2018/2146080.

3.

Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine. 2018;97(37):e12390. https://doi.org/10.1097/MD.0000000000012390. (Wolters Kluwer Health).CrossRefPubMedPubMedCentral

4.

Gaddam SJ, Chesnut GT. Testicle Cancer. StatPearls [En ligne]. StatPearls Publishing; 2023 [cité le 30 août 2023]; Disponible: https://www.ncbi.nlm.nih.gov/books/NBK563159/.

5.

Crocetto F, Arcaniolo D, Napolitano L, Barone B, La Rocca R, Capece M, et al. Impact of sexual activity on the risk of male genital tumors: a systematic review of the literature. Int J Environ Res Public Health. 2021;18(16):8500. https://doi.org/10.3390/IJERPH18168500.CrossRefPubMedPubMedCentral

6.

Zhang T, Ji L, Liu B, Guan W, Liu Q, Gao Y. Testicular germ cell tumors: a clinicopathological and immunohistochemical analysis of 145 cases. Int J Clin Exp Pathol [En ligne]. e-Century Publishing Corporation; 2018 [cité le 4 septembre 2023];11(9):4622. Disponible: /pmc/articles/PMC6962990/.

7.

Reese SW, Tully KH, Nabi J, Paciotti M, Chou WH, Trinh QD. Temporal trends in the incidence of testicular cancer in the United States over the past four decades. Eur Urol Oncol. 2021;4(5):834–6. https://doi.org/10.1016/J.EUO.2020.06.011.CrossRefPubMed

8.

Hale GR, Teplitsky S, Truong H, Gold SA, Bloom JB, Agarwal PK. Lymph node imaging in testicular cancer. Transl Androl Urol. 2018;7(5):864–74. https://doi.org/10.21037/TAU.2018.07.18.CrossRefPubMedPubMedCentral

9.

Herrera Ortiz AF, FernándezBeaujon LJ, GarcíaVillamizar SY, Fonseca López FF. Magnetic resonance versus computed tomography for the detection of retroperitoneal lymph node metastasis due to testicular cancer: a systematic literature review. Eur J Radiol Open. 2021;8:100372. https://doi.org/10.1016/J.EJRO.2021.100372.CrossRefPubMedPubMedCentral

10.

Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JES, Dearnaley DP, et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol. 2009;64(4):362–7. https://doi.org/10.1016/J.CRAD.2008.10.011.CrossRefPubMed

11.

Langberg CW, Baco E, Lauritzen P, Sandbæk G, Rud E. MRI in the follow-up of testicular cancer: less is more. Anticancer Res. 2019;39(6):2963–8. https://doi.org/10.21873/ANTICANRES.13427. (International Institute of Anticancer Research).CrossRefPubMed

12.

Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys. 2012;83(4):e445-52. https://doi.org/10.1016/j.ijrobp.2012.01.044. (Elsevier).CrossRefPubMed

13.

Hansen J, Jurik AG. Diagnostic value of multislice computed tomography and magnetic resonance imaging in the diagnosis of retroperitoneal spread of testicular cancer: a literature review. Acta Radiol. 2009;50(9):1064–70. https://doi.org/10.3109/02841850903220371.CrossRefPubMed

14.

Enei Y, Urabe F, Miki J, Iwatani K, Hisakane A, Yasue K, et al. Clear identification of the rare solitary external iliac lymph node metastasis of testicular cancer by using indocyanine green fluorescence guidance. IJU Case Rep. 2021;4(3):163. https://doi.org/10.1002/IJU5.12273. (Wiley-Blackwell).CrossRefPubMedPubMedCentral

15.

Daugaard G, Karas V, Sommer P. Inguinal metastases from testicular cancer. BJU Int. 2006;97(4):724–6. https://doi.org/10.1111/J.1464-410X.2006.06017.X.CrossRefPubMed

16.

Nicolai N, Tarabelloni N, Gasperoni F, Catanzaro M, Stagni S, Torelli T, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: safety and efficacy analyses at a high volume center. J Urol. 2018;199(3):741–7. https://doi.org/10.1016/J.JURO.2017.09.088. (Wolters Kluwer Philadelphia, PA).CrossRefPubMed

17.

Yang H, Obiora D, Tomaszewski JJ. Outcomes and expanding indications for robotic retroperitoneal lymph node dissection for testicular cancer. Transl Androl Urol. 2021;10(5):2188. https://doi.org/10.21037/TAU.2020.03.14.CrossRefPubMedPubMedCentral

18.

Tran V, Gibson L, Sengupta S. Retroperitoneal lymph node dissection for germ cell tumour. Transl Androl Urol. 2020;9(6):3103. https://doi.org/10.21037/TAU-2019-SUC-18. (AME Publications).CrossRefPubMedPubMedCentral

19.

Skinner DG, Leadbetter WF. The surgical management of testis tumors. J Urol. Wolters Kluwer Philadelphia, PA; 1971;106(1):84–93. https://doi.org/10.1016/S0022-5347(17)61231-X.

20.

Ray B, Hajdu SI, Whitmore WF. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. 1974;33(2):340–8. https://doi.org/10.1002/1097-0142(197402)33:2%3c340::aid-cncr2820330207%3e3.0.co;2-y.CrossRefPubMed

21.

Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol. 1987;138(1):77–82. https://doi.org/10.1016/S0022-5347(17)42997-1.CrossRefPubMed

22.

Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315–20. https://doi.org/10.1016/S0022-5347(17)52904-3.CrossRefPubMed

23.

Zarifmahmoudi L, Ghorbani H, Sadeghi R, Sadri K, Soltani S, Aghaee A. Sentinel lymph node mapping in post chemotherapy nonseminoma testicular cancer patients undergoing retroperitoneal lymph node dissection: a series of nine cases. Asia Ocean J Nucl Med Biol. 2022;10(1):36–42. https://doi.org/10.22038/AOJNMB.2021.55218.1380.CrossRefPubMedPubMedCentral

24.

Brouwer OR, Olmos RAV, Vermeeren L, Hoefnagel CA, Nieweg OE, Horenblas S. SPECT/CT and a portable gamma-camera for image-guided laparoscopic sentinel node biopsy in testicular cancer. J Nucl Med. 2011;52(4):551–4. https://doi.org/10.2967/JNUMED.110.086660.CrossRefPubMed

25.

Satoh M, Ito A, Kaiho Y, Nakagawa H, Saito S, Endo M, et al. Intraoperative, radio-guided sentinel lymph node mapping in laparoscopic lymph node dissection for Stage I testicular carcinoma. Cancer. 2005;103(10):2067–72. https://doi.org/10.1002/CNCR.21049.CrossRefPubMed

26.

Ohyama C, Chiba Y, Yamazaki T, Endoh M, Hoshi S, Arai Y. Lymphatic mapping and gamma probe guided laparoscopic biopsy of sentinel lymph node in patients with clinical stage I testicular tumor. J Urol. 2002;168(4 Pt 1):1390–5. https://doi.org/10.1016/S0022-5347(05)64456-4.CrossRefPubMed

27.

Blok JM, Kerst JM, Vegt E, Brouwer OR, Meijer RP, Bosch JLHR, et al. Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease. BJU Int. 2019;124(3):424–30. https://doi.org/10.1111/BJU.14618.CrossRefPubMedPubMedCentral

28.

Paly JJ, Efstathiou JA, Hedgire SS, Chung PWM, O’Malley M, Shah A, et al. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol. 2013;106(1):64–8. https://doi.org/10.1016/J.RADONC.2012.12.002.CrossRefPubMed

29.

Gerdtsson A, Thor A, Grenabo Bergdahl A, Almås B, Håkansson U, Törnblom M, et al. Unilateral or bilateral retroperitoneal lymph node dissection in nonseminoma patients with postchemotherapy residual tumour? Results from RETROP, a population-based mapping study by the Swedish Norwegian Testicular Cancer Group. Elsevier; 2022;5(2):235–43. https://doi.org/10.1016/J.EUO.2021.02.002.

30.

Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology. 2006;67(1):199.e7-199.e8. https://doi.org/10.1016/J.UROLOGY.2005.07.022.CrossRef

31.

Rukstalis DB, Chodak GW, Richie JP, Rowland RG. Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol. 1992;148(6):1907–9. https://doi.org/10.1016/S0022-5347(17)37068-4.CrossRefPubMed

32.

Jewett MAS, Kong YSP, Goldberg SD, Sturgeon JFG, Thomas GM, Alison RE, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139(6):1220–3. https://doi.org/10.1016/S0022-5347(17)42869-2.CrossRefPubMed

33.

Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2I):287–91. https://doi.org/10.1016/S0022-5347(17)39434-X.CrossRefPubMed

34.

Sago AL, Ball TP, Novicki DE. Complications of retroperitoneal lymphadenectomy. Urology. Elsevier; 1979;13(3):241–3. DOI: https://doi.org/10.1016/0090-4295(79)90410-2.

35.

Staubitz WJ, Early KS, Magoss I V., Murphy GP. Surgical management of testis tumor. J Urol. No longer published by Elsevier; 1974;111(2):205–9. DOI: https://doi.org/10.1016/S0022-5347(17)59928-0.

36.

Yadav K. Retroperitoneal lymph node dissection: an update in testicular malignancies. Clin Transl Oncol 2017;19(7):793–8. DOI: https://doi.org/10.1007/S12094-017-1622-5.

37.

Mano R, Di Natale R, Sheinfeld J. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol. 2019;37(3):209–18. https://doi.org/10.1016/J.UROLONC.2018.09.009.CrossRefPubMed

38.

Steiner H, Peschel R, Bartsch G. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int. 2008;102(3):310–4. https://doi.org/10.1111/J.1464-410X.2008.07579.X.CrossRefPubMed

39.

Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149(2):237–43. https://doi.org/10.1016/S0022-5347(17)36046-9.CrossRefPubMed

40.

Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol. 1990;144(5):1160–3. https://doi.org/10.1016/S0022-5347(17)39681-7.CrossRefPubMed

41.

Masterson TA, Cary C, Rice KR, Foster RS. The evolution and technique of nerve-sparing retroperitoneal lymphadenectomy. Urol Clinics North Am. Elsevier; 2015;42(3):311–20. https://doi.org/10.1016/J.UCL.2015.04.005.

42.

Beveridge TS, Allman BL, Johnson M, Power A, Sheinfeld J, Power NE. Retroperitoneal lymph node dissection: anatomical and technical considerations from a cadaveric study. J Urol. NIH Public Access; 2016;196(6):1764. https://doi.org/10.1016/J.JURO.2016.06.091.

43.

Beveridge TS, Fournier DE, Groh AMR, Johnson M, Power NE, Allman BL. The anatomy of the infrarenal lumbar splanchnic nerves in human cadavers: implications for retroperitoneal nerve‐sparing surgery. J Anat. Wiley-Blackwell; 2018;232(1):124. https://doi.org/10.1111/JOA.12721.

44.

Colleselli K, Poisel S, Schachtner W, Bartsch G. Nerve-preserving bilateral retroperitoneal lymphadenectomy: anatomical study and operative approach. J Urol. No longer published by Elsevier; 1990;144(2):293–7. https://doi.org/10.1016/S0022-5347(17)39435-1.

45.

Aufderklamm S, Todenhöfer T, Hennenlotter J, Gakis G, Mischinger J, Mundhenk J, et al. [Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer: a technique to reduce morbidity]. Urologe A; 2013;52(8):1097–103. https://doi.org/10.1007/S00120-013-3133-5.

46.

Mittakanti HR, Porter JR. Robotic retroperitoneal lymph node dissection for testicular cancer: feasibility and latest outcomes. Curr Opin Urol. Lippincott Williams and Wilkins; 2019;29(2):173–9. https://doi.org/10.1097/MOU.0000000000000582.

47.

Kenney PA, Tuerk IA. Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol. 2008;26(6):561–9. https://doi.org/10.1007/S00345-008-0299-3.CrossRefPubMed

48.

Umbreit EC, McIntosh AG, Suk-ouichai C, Segarra LA, Holland LC, Fellman BM, et al. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020;126(22):4878–85. https://doi.org/10.1002/CNCR.33051.CrossRefPubMed

49.

Yarmohammadi H, Schilsky J, Durack JC, Brody LA, Asenbaum U, Velayati S, et al. Treatment of Chylous Ascites with Peritoneovenous Shunt (Denver Shunt) following retroperitoneal lymph node dissection in patients with urological malignancies: update of efficacy and predictors of complications. J Urol. 2020;204(4):818–22. https://doi.org/10.1097/JU.0000000000001121.CrossRefPubMedPubMedCentral

50.

Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, et al. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M D. Anderson experience. J Urol. 2006;176(4 Pt 1):1463–7. https://doi.org/10.1016/J.JURO.2006.06.016.CrossRefPubMed

51.

Cary C, Foster RS, Masterson TA. Complications of retroperitoneal lymph node dissection. Urol Clin North Am. 2019;46(3):429–37. https://doi.org/10.1016/J.UCL.2019.04.012.CrossRefPubMed

52.

Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol. 2010;28(5):504–9. https://doi.org/10.1016/J.UROLONC.2008.10.026.CrossRefPubMed

53.

Cary C, Masterson TA, Bihrle R, Foster RS. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: additional procedures and perioperative complications. Urol Oncol. 2015;33(9):389.e15-389.e21. https://doi.org/10.1016/J.UROLONC.2014.07.013.CrossRefPubMed

54.

Groeben C, Koch R, Nestler T, Kraywinkel K, Borkowetz A, Wenzel S, et al. Centralization tendencies of retroperitoneal lymph node dissection for testicular cancer in Germany? A total population-based analysis from 2006 to 2015. World J Urol. 2020;38(7):1765–72. https://doi.org/10.1007/S00345-019-02972-8.CrossRefPubMed

55.

Heidenreich A, Albers P, Hartmann M, Kliesch S, Köhrmann KU, Krege S, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol. Wolters KluwerPhiladelphia, PA; 2003;169(5):1710–4. https://doi.org/10.1097/01.JU.0000060960.18092.54.

56.

Notarfrancesco M, Fankhauser CD, Lorch A, Ardizzone D, Helnwein S, Hoch D, et al. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland – a retrospective chart review. Swiss Med Wkly. NLM (Medline); 2023;153(4):40053–40053. https://doi.org/10.57187/SMW.2023.40053.

57.

Ruf CG, Krampe S, Matthies C, Anheuser P, Nestler T, Simon J, et al. Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature. World J Surg Oncol. NLM (Medline); 2020;18(1):253. https://doi.org/10.1186/S12957-020-02032-1/TABLES/5.

58.

Williams SB, Kacker R, Steele GS, Richie JP. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy. Urol Oncol: Seminars Orig Investig. Elsevier; 2012;30(1):60–3. https://doi.org/10.1016/J.UROLONC.2009.12.006.

59.

Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of primary retroperitoneal lymph node dissection. J Urol. 1994;152(2):424–7.CrossRefPubMed

60.

Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153(3):976–80.PubMed

61.••

Ge S, Gan L, Meng C, Li K, Wang Z, Zeng Z, et al. Comparison of the perioperative outcomes of laparoscopic and open retroperitoneal lymph node dissection for low-stage (stage I/II) testicular germ cell tumors: a systematic review and meta-analysis. Int J Surg 2023;109(4). https://doi.org/10.1097/JS9.0000000000000321. This systematic review and meta-analysis examine the outcomes related to the frequency of complications between open and laparoscopic RPLND, affirming the safety of laparoscopic approaches in patients with TC.

62.

Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European Perspective. Eur Urol. Elsevier; 2008;54(5):1004–19. https://doi.org/10.1016/J.EURURO.2008.08.022.

63.•

Grenabo Bergdahl A, Månsson M, Holmberg G, Fovaeus M. Robotic retroperitoneal lymph node dissection for testicular cancer at a national referral centre. BJUI Compass 2022;3(5):363–70. https://doi.org/10.1002/BCO2.149. This study provides data on the incidence of complications following robotic RPLND, affirming the safety of this approach.

64.

Bhanvadia R, Ashbrook C, Bagrodia A, Lotan Y, Margulis V, Woldu S. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. World J Urol. 2021;39(6):1977–84. https://doi.org/10.1007/S00345-020-03403-9.CrossRefPubMed

65.

Li R, Duplisea JJ, Petros FG, González GMN, Tu SM, Karam JA, et al. Robotic postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Eur Urol Oncol. 2021;4(4):651–8. https://doi.org/10.1016/J.EUO.2019.01.014.CrossRefPubMed

66.

Wells H, Hayes MC, O’Brien T, Fowler S. Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study. BJU Int. 2017;119(1):91–9. https://doi.org/10.1111/BJU.13569.CrossRefPubMed

67.

Harris KT, Gorin MA, Ball MW, Pierorazio PM, Allaf ME. A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. BJU Int. John Wiley & Sons, Ltd; 2015;116(6):920–3. https://doi.org/10.1111/BJU.13121.

68.

Xu Y, Li H, Wang B, Gu L, Gao Y, Fan Y, et al. Robotic versus laparoscopic retroperitoneal lymph node dissection for clinical stage I non-seminomatous germ cell tumor of testis: a comparative analysis. Urol J. 2021;18(6):618–22. https://doi.org/10.22037/UJ.V18I.6629.CrossRefPubMed

69.

Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, et al. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. Springer Science and Business Media Deutschland GmbH; 2022;40(6):1505–12. https://doi.org/10.1007/S00345-022-03974-9/METRICS.

70.

Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, et al. Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumour: a population-based study from the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol. 2020;3(3):382–9. https://doi.org/10.1016/J.EUO.2019.08.002.CrossRefPubMed

71.

Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Eur Urol. 2013;63(6):1013–7. https://doi.org/10.1016/J.EURURO.2012.09.036.CrossRefPubMed

72.

Notarfrancesco M, Fankhauser CD, Lorch A, Ardizzone D, Helnwein S, Hoch D, et al. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review. Swiss Med Wkly. 2023;153:40053. https://doi.org/10.57187/SMW.2023.40053.CrossRefPubMed

73.

Cresswell J, Scheitlin W, Gozen A, Lenz E, Teber D, Rassweiler J. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. BJU Int. John Wiley & Sons, Ltd; 2008;102(7):844–8. https://doi.org/10.1111/J.1464-410X.2008.07754.X.

74.

Nicolai N, Cattaneo F, Biasoni D, Catanzaro M, Torelli T, Zazzara M, et al. Laparoscopic postchemotherapy retroperitoneal lymph-node dissection can be a standard option in defined nonseminomatous germ cell tumor patients. https://home.liebertpub.com/end. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA ; 2016;30(10):1112–9. https://doi.org/10.1089/END.2016.0458.

75.

Beck SDW, Bey AL, Bihrle R, Foster RS. Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. J Urol. Wolters Kluwer Philadelphia, PA; 2010;184(5):2078–80. https://doi.org/10.1016/J.JURO.2010.06.146.

76.

Miki T, Mizutani Y, Nakamura T, Kawauchi A, Nagahara A, Nonomura N, et al. Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor. Int J Urol. 2009;16(4):379–82. https://doi.org/10.1111/J.1442-2042.2009.02251.X.CrossRefPubMed

77.

Guner E, Seker KG. La relación albúmina/globulina preoperatoria como factor pronóstico en pacientes con cáncer testicular. Actas Urol Esp. Elsevier Doyma; 2020;44(7):469–76. https://doi.org/10.1016/J.ACURO.2020.03.011.

78.•

Williams SB, Kacker R, Winston D, Bahnson E, Steele GS, Richie JP. Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer. J Urol. Wolters KluwerPhiladelphia, PA; 2011;186(6):2245–8. https://doi.org/10.1016/J.JURO.2011.07.101. The article outlines established factors that significantly elevate the probability of detecting cancer cells in lymph nodes in individuals with TC..

79.•

Gorgel SN, Akin Y, Koc EM, Kose O, Ozcan S, Yilmaz Y. Impact of increased aspartate aminotransferase to alanine aminotransferase (De Ritis) ratio in prognosis of testicular cancer. Investig Clin Urol. Korean Urological Association; 2019;60(3):169. https://doi.org/10.4111/ICU.2019.60.3.169. The article presents the findings of a study that assesses the impact of the De Ritis ratio on the likelihood of metastases in lymph nodes in TC..

80.

Olcucu MT, Karamik K, Yilmaz K, Okuducu Y, Cakir S, Ates M. Preoperative inflammation markers and De Ritis ratio in predicting clinical presentation and prognosis of patients with testicular germ cell tumors. J Coll Physicians Surg Pak. 2020;30(10):1041–6. https://doi.org/10.29271/JCPSP.2020.10.1041.CrossRefPubMed

81.

Finelli A. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: long-term oncologic outcomes. Curr Opin Urol. 2008;18(2):180–4. https://doi.org/10.1097/MOU.0b013e3282f4a880.CrossRefPubMed

82.

Mano R, Di Natale R, Sheinfeld J. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol: Seminars Orig Investig. 2019;37(3):209–18. https://doi.org/10.1016/j.urolonc.2018.09.009.CrossRef

83.

Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman D, et al. Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer. John Wiley & Sons, Ltd; 2010;116(22):5243–50. https://doi.org/10.1002/CNCR.25266.

84.

Mottaran A, Ercolino A, Bianchi L, Piazza P, Manes F, Amirhassankhani S, et al. Twenty years’ experience in retroperitoneal lymph node dissection for testicular cancer in a tertiary referral center. Medicina (Kaunas). 2023;59(1):133. https://doi.org/10.3390/MEDICINA59010133.CrossRefPubMed

85.••

Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, et al. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol 2022;40(6):1505–12. https://doi.org/10.1007/S00345-022-03974-9. This article details the safety and oncological outcomes of minimally invasive RPLND for TC through a retrospective multi-center cohort study.

86.

Supron AD, Cheaib JG, Biles MJ, Schwen Z, Allaf M, Pierorazio PM. Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. J Robot Surg. 2021;15(2):309–13. https://doi.org/10.1007/S11701-020-01107-1.CrossRefPubMed

87.

Rocco NR, Stroup SP, Abdul-Muhsin HM, Marshall MT, Santomauro MG, Christman MS, et al. Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes. World J Urol. 2020;38(4):859–67. https://doi.org/10.1007/S00345-019-02900-W.CrossRefPubMed

88.

Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, et al. Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. Eur Urol. 2017;71(3):476–82. https://doi.org/10.1016/J.EURURO.2016.05.017.CrossRefPubMed

89.

Nakamura T, Kawauchi A, Oishi M, Ueda T, Shiraishi T, Nakanishi H, et al. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors. Int J Clin Oncol. 2016;21(4):791–5. https://doi.org/10.1007/S10147-015-0934-0.CrossRefPubMed

90.

Hiester A, Nini A, Fingerhut A, Siemer RG, Winter C, Albers P, et al. Preservation of ejaculatory function after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testicular cancer: template vs. bilateral resection. Front Surg 2019;5. https://doi.org/10.3389/FSURG.2018.00080.

91.

Nowroozi M, Ayati M, Arbab A, Jamshidian H, Ghorbani H, Niroomand H, et al. Postchemotherapy retroperitoneal lymph node dissection in patients with nonseminomatous testicular cancer: a single center experiences. Nephrourol Mon. Brieflands; 2015;7(5):27343. https://doi.org/10.5812/NUMONTHLY.27343.

92.

Oldenburg J, Alfsen GC, Lien HH, Aass N, Wæhre H, Fosså SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21(17):3310–7. https://doi.org/10.1200/JCO.2003.03.184.CrossRefPubMed

93.

Busch J, Magheli A, Erber B, Friedersdorff F, Hoffmann I, Kempkensteffen C, et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. BMC Urol 2012;12. https://doi.org/10.1186/1471-2490-12-15.

94.

Luz MA, Kotb AF, Aldousari S, Brimo F, Tanguay S, Kassouf W, et al. Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol. 2010;8. https://doi.org/10.1186/1477-7819-8-97.

95.

Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55(1):217–26. https://doi.org/10.1016/J.EURURO.2008.09.027.CrossRefPubMed

96.

Ehrlich Y, Yossepowitch O, Kedar D, Baniel J. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int. 2006;97(6):1221–4. https://doi.org/10.1111/J.1464-410X.2006.06167.X.CrossRefPubMed

97.

Singh P, Yadav S, Mahapatra S, Seth A. Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors. Indian J Urol. 2016;32(1):40–4. https://doi.org/10.4103/0970-1591.173102.CrossRefPubMedPubMedCentral

98.

Tanaka T, Kitamura H, Kunishima Y, Takahashi S, Takahashi A, Masumori N, et al. Modified and bilateral retroperitoneal lymph node dissection for testicular cancer: peri- and postoperative complications and therapeutic outcome. Jpn J Clin Oncol. 2006;36(6):381–6. https://doi.org/10.1093/JJCO/HYL026.CrossRefPubMed

99.

Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, et al. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007;177(1):131–8. https://doi.org/10.1016/J.JURO.2006.08.092.CrossRefPubMed

100.

Ariffin NA, Nason GJ, Omer SI, Considine SW, Sweeney P, Power DG. Post-chemotherapy retroperitoneal lymph node dissection in patients with non-seminomatous germ cell tumour (NSGCT). Ir Med J. 2017;110(10):647–647.PubMed

101.

Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol. 2023;41(16):3009–18. https://doi.org/10.1200/JCO.22.00624.CrossRefPubMed

102.

Cho JS, Kaimakliotis HZ, Cary C, Masterson TA, Beck S, Foster R. Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. BJU Int. 2017;120(1):104–8. https://doi.org/10.1111/BJU.13844.CrossRefPubMed

103.

El Sayed S, Grando JPS, De Almeida SHM, Mortati Neto N, Moreira HA. Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection. Int Braz J Urol. 2004;30(5):384–8. https://doi.org/10.1590/S1677-55382004000500005.CrossRefPubMed

104.

Calestroupat JP, Sanchez-Salas R, Cathelineau X, Rozet F, Galiano M, Smyth G, et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. J Endourol. 2009;23(4):645–50. https://doi.org/10.1089/END.2008.0423.CrossRefPubMed

105.

Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, et al. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: a multi-institutional retrospective cohort study. Eur J Cancer Eur J Cancer. 2023;182:144–54. https://doi.org/10.1016/J.EJCA.2022.12.032.CrossRefPubMed

106.

Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. John Wiley & Sons, Ltd; 2007;109(3):528–35. https://doi.org/10.1002/CNCR.22440.

107.

Raja A, Malik K, Kathiresan N, Radhakrishnan V. Nerve-sparing Postchemotherapy Retroperitoneal Lymph Node Dissection (PC RPLND) for nonseminomatous germ cell tumour: experience from a tertiary cancer centre. Indian J Surg Oncol. 2021;12(2):374–7. https://doi.org/10.1007/S13193-021-01313-9.CrossRefPubMedPubMedCentral

108.

Kalemci S, Kizilay F, Ergun KE, Aliyev B, Simsir A. Postchemotherapy retroperitoneal residual mass resection for germ cell testicular tumors: a single-center experience. Rev Assoc Med Bras (1992). 2022;68(4):524–9. https://doi.org/10.1590/1806-9282.20211247.CrossRefPubMed

109.

Kimura Y, Nakamura T, Kawauchi A, Kawabata G, Hongo F, Miki T. Post-chemotherapy nerve-sparing laparoscopic retroperitoneal lymph node dissection in stage IIB testicular cancer. Int J Urol. 2013;20(8):837–41. https://doi.org/10.1111/IJU.12072.CrossRefPubMed

110.

Aufderklamm S, Todenhöfer T, Hennenlotter J, Gakis G, Mischinger J, Mundhenk J, et al. Bilateral laparoscopic postchemotherapy retroperitoneal lymph-node dissection in nonseminomatous germ cell tumors–a comparison to template dissection. J Endourol. 2013;27(7):856–61. https://doi.org/10.1089/END.2012.0648.CrossRefPubMed

111.

Gaya JM, Palou J, Peña JA, Rosales A, Maroto P, Sullivan I, et al. ¿Existe un límite para el abordaje laparoscópico de la masa residual retroperitoneal posquimioterapia? Actas Urol Esp. Elsevier Doyma; 2015;39(4):264–7. https://doi.org/10.1016/J.ACURO.2014.10.008.

112.

Arai Y, Kaiho Y, Yamada S, Saito H, Mitsuzuka K, Yamashita S, et al. Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. Int Urol Nephrol. Springer; 2012;44(5):1389–95. https://doi.org/10.1007/S11255-012-0195-Z/METRICS.

113.

Maldonado-Valadez R, Schilling D, Anastasiadis AG, Sturm W, Stenzl A, Corvin S. Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J Endourol. Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA ; 2008;21(12):1501–4. https://doi.org/10.1089/END.2006.0441.

114.

Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. https://home.liebertpub.com/end. Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA ; 2005;19(6):683–92. https://doi.org/10.1089/END.2005.19.683.

115.

Palese MA, Su LM, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology. Elsevier; 2002;60(1):130–4. https://doi.org/10.1016/S0090-4295(02)01670-9.

116.

Islamoğlu E, Özsoy Ç, Anil H, Aktaş Y, Ateş M, Savaş M. Post-chemotherapy robot-assisted retroperitoneal lymph node dissection in non-seminomatous germ cell tumor of testis: feasibility and outcomes of initial cases. Turk J Urol. Turkish Association of Urology; 2019;45(2):113. https://doi.org/10.5152/TUD.2018.99390.

117.

Tamhankar AS, Patil SR, Ojha SP, Ahluwalia P, Gautam G. Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience. J Robot Surg. Springer London; 2019;13(6):747–56. https://doi.org/10.1007/S11701-018-00903-0/METRICS.

118.

Kamel MH, Littlejohn N, Cox M, Eltahawy EA, Davis R. Post-chemotherapy robotic retroperitoneal lymph node dissection: institutional experience. https://home.liebertpub.com/end. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA ; 2016;30(5):510–9. https://doi.org/10.1089/END.2015.0673.

119.

Stepanian S, Patel M, Porter J. Robot-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer: evolution of the technique. Eur Urol. Elsevier; 2016;70(4):661–7. https://doi.org/10.1016/J.EURURO.2016.03.031.

120.

Singh A, Chatterjee S, Bansal P, Bansal A, Rawal S. Robot-assisted retroperitoneal lymph node dissection: feasibility and outcome in postchemotherapy residual mass in testicular cancer. Indian J Urol. Wolters Kluwer -- Medknow Publications; 2017;33(4):304. https://doi.org/10.4103/IJU.IJU_8_17.

121.

Kordan Y, Köseoğlu E, Esen B, Özkan A, Kiremit MC, Kılıç M, et al. Postchemotherapy robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumors in the lateral decubitus position: oncological and functional outcomes. World J Urol. Springer Science and Business Media Deutschland GmbH; 2023;41(4):1101–7. https://doi.org/10.1007/S00345-023-04329-8/METRICS.

122.•

Abdul-Muhsin H, Rocco N, Navaratnam A, Woods M, L’Esperance J, Castle E, et al. Outcomes of post-chemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multi-institutional study. World J Urol. Springer Science and Business Media Deutschland GmbH; 2021;39(10):3833–8. https://doi.org/10.1007/S00345-021-03712-7/METRICS. The article evaluates outcomes in TC patients undergoing post-chemotherapy robot-assisted RPLND through retrospective analysis.

123.

Ghoreifi A, Mitra AP, McClintock G, Baky F, McDowell Z, Lavallée E, et al. Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: a multicenter collaborative study. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2023;41(2):111.e7–111.e14. https://doi.org/10.1016/J.UROLONC.2022.11.006.

124.

Rabbani F, Sheinfeld J, Farivar-Mohseni H, Leon A, Rentzepis MJ, Reuter VE, et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol. 2001;19(7):2020–5. https://doi.org/10.1200/JCO.2001.19.7.2020.CrossRefPubMed

125.

Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23(12):2781–8. https://doi.org/10.1200/JCO.2005.07.132.CrossRefPubMed

126.

Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol. 2004;22(3):464–7. https://doi.org/10.1200/JCO.2004.07.178.CrossRefPubMed

127.

Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol. 2005;174(2):557–60. https://doi.org/10.1097/01.JU.0000165163.03805.37.CrossRefPubMed

128.

Steiner H, Zangerl F, Stöhr B, Granig T, Ho H, Bartsch G, et al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol. 2008;180(4):1348–53. https://doi.org/10.1016/J.JURO.2008.06.040.CrossRefPubMed

129.

Nielsen ME, Lima G, Schaeffer EM, Porter J, Cadeddu JA, Tuerk I, et al. Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. Urology. 2007;70(6):1168–72. https://doi.org/10.1016/J.UROLOGY.2007.08.041.CrossRefPubMed

130.

Böhlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol. Lippincott Williams and Wilkins; 1999;161(4):1148–52. https://doi.org/10.1016/S0022-5347(01)61615-X.

131.

EAU Guidelines. Edn. In: Proceedings of the EAU Annual Congress Milan 2023, Milan, Italy, 10–13 March 2023. Arnhem, The Netherlands: EAU Guidelines Office; 2023.

132.

Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. Wolters Kluwer Philadelphia, PA; 2019;202(2):272–81. https://doi.org/10.1097/JU.0000000000000318.

133.

Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. Elsevier Ltd; 2022;33(4):362–75. https://doi.org/10.1016/J.ANNONC.2022.01.002.

134.

Joice GA, Rowe SP, Gorin MA, Pierorazio PM. Molecular imaging for evaluation of viable testicular cancer nodal metastases. Curr Urol Rep. Current Medicine Group LLC 1; 2018;19(12):1–7. https://doi.org/10.1007/S11934-018-0863-3/METRICS.

135.

[En ligne]. National Comprehensive Cancer Network - Home [cité le 12 septembre 2023]. Disponible: https://www.nccn.org/.

136.

Pierre T, Selhane F, Zareski E, Garcia C, Fizazi K, Loriot Y, et al. The role of CT in the staging and follow-up of testicular tumors: baseline, recurrence and pitfalls. Cancers (Basel). 2022;14(16). https://doi.org/10.3390/CANCERS14163965.

137.

Hudolin T, Kastelan Z, Knezevic N, Goluza E, Tomas D, Coric M. Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol. 2012;20(1):15–8. https://doi.org/10.1177/1066896911431452.CrossRefPubMed

138.

Lien HH, Stenwig AE, Ous S, Fosså SD. Influence of different criteria for abnormal lymph node size on reliability of computed tomography in patients with non-seminomatous testicular tumor. Acta Radiol Diagn (Stockh). 1986;27(2):199–203. https://doi.org/10.1177/028418518602700212.

139.

Stomper PC, Fung CY, Socinski MA, Jochelson MS, Garnick MB, Richie JP. Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. AJR Am J Roentgenol. 1987;149(6):1187–90. https://doi.org/10.2214/AJR.149.6.1187.CrossRefPubMed

140.

Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. American Public Health Association; 2013;169(2):521–5. https://doi.org/10.2214/AJR.169.2.9242768.

141.

Kreydin EI, Barrisford GW, Feldman AS, Preston MA. Testicular cancer: what the radiologist needs to know. AJR Am J Roentgenol. 2013;200(6):1215–25. https://doi.org/10.2214/AJR.12.10319.

142.

Larsen SKA, Agerbæk M, Jurik AG, Pedersen EM. Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. Acta Oncol 2020;59(11):1374–81. https://doi.org/10.1080/0284186X.2020.1794035.

143.

Tasu JP, Faye N, Eschwege P, Rocher L, Bléry M. Imaging of burned-out testis tumor: five new cases and review of the literature. J Ultrasound Med. 2003;22(5):515–21. https://doi.org/10.7863/JUM.2003.22.5.515.CrossRefPubMed

144.

Mearini L, Nunzi E, Di Biase M, Silvi E, Sabatini I, Porena M. Robotic retroperitoneal lymph node dissection in advanced stage disease. Urol Int. S. Karger AG; 2016;97(4):380–5. https://doi.org/10.1159/000450924.

145.

Laukka M, Mannisto S, Beule A, Kouri M, Blomqvist C. Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. Acta Oncol. 2020;59(6):660–5. https://doi.org/10.1080/0284186X.2020.1725243.CrossRefPubMed

146.

Ellis JH, Bies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP. Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. J Comput Assist Tomogr. 1984;8(4):709–19. https://doi.org/10.1097/00004728-198408000-00023.

147.

Schoch J, Haunschild K, Strauch A, Nestler K, Schmelz H, Paffenholz P, et al. German specialists treating testicular cancer follow different guidelines with resulting inconsistency in assessment of retroperitoneal lymph-node metastasis: clinical implications and possible corrective measures. World J Urol. Springer; 2023;41(5):1353. https://doi.org/10.1007/S00345-023-04364-5.

148.

Tandstad T, Ståhl O, Håkansson U, Wahlqvist R, Klepp O, Cavallin-Ståhl E, et al. The SWENOTECA group: a good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway. Scand J Urol. 2016;50(1):9–13. https://doi.org/10.3109/21681805.2015.1059360.CrossRefPubMed

149.

Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102–25. https://doi.org/10.1593/NEO.81328.CrossRefPubMedPubMedCentral

150.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology. Elsevier; 2018;29(8):1658–86. https://doi.org/10.1093/ANNONC/MDY217.

151.

Nanni C, Zanoni L, Fanti S. Nuclear medicine in urological cancers: what is new? Future Oncol. 2014;10(13):2061–72. https://doi.org/10.2217/FON.14.87.CrossRefPubMed

152.

De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. World J Urol. Springer; 2004;22(1):41–6. https://doi.org/10.1007/S00345-004-0403-2/METRICS.

153.

Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. John Wiley & Sons, Ltd; 2002;94(9):2353–62. https://doi.org/10.1002/CNCR.10494.

154.

Nuutinen JM, Leskinen S, Elomaa I, Minn H, Varpula M, Solin O, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. European Journal of Cancer Part A. Elsevier; 1997;33(8):1234–41. https://doi.org/10.1016/S0959-8049(97)00111-1.

155.

Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. Am Soc Clin Oncol. 2016;14(5):1637–41. https://doi.org/10.1200/JCO.1996.14.5.1637.CrossRef

156.

de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Annals of Oncology. Elsevier; 2008;19(9):1619–23. https://doi.org/10.1093/annonc/mdn170.

157.

Huddart RA, O’Doherty MJ, Padhani A, Rustin GJS, Mead GM, Joffe JK, et al. 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC trial TE22 - The NCRI testis tumour clinical study group. Journal of Clinical Oncology. American Society of Clinical Oncology; 2007;25(21):3090–5. https://doi.org/10.1200/JCO.2006.09.3831.

158.

Xia L, Venegas OG, Predina JD, Singhal S, Guzzo TJ. Intraoperative molecular imaging for post-chemotherapy robot-assisted laparoscopic resection of seminoma metastasis: a case report. Clin Genitourin Cancer. Elsevier Inc.; 2017;15(1):e61–4. https://doi.org/10.1016/j.clgc.2016.09.007.

159.

Alongi P, Evangelista L, Caobelli F, Spallino M, Gianolli L, Midiri M, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(1):85–94. https://doi.org/10.1007/S00259-017-3811-4.CrossRefPubMed

160.

Woldu SL, Meng X, Wong D, Baky F, Margulis V, Xi Y, et al. Performance characteristics of 18F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection. Can Urol Assoc J. 2022;16(3). https://doi.org/10.5489/CUAJ.7317.

161.

Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 2019;201(2):322–30. https://doi.org/10.1016/J.JURO.2018.08.050.CrossRefPubMedPubMedCentral

162.

Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 2015;40(8):e386-91. https://doi.org/10.1097/RLU.0000000000000849.CrossRefPubMed

163.

Harisinghani MG, Saksena M, Ross RW, Tabatabaei S, Dahl D, McDougal S, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology. 2005;66(5):1066–71. https://doi.org/10.1016/J.UROLOGY.2005.05.049.CrossRefPubMed

164.

Charron CL, Hou J, McFarland MS, Dhanvantari S, Kovacs MS, Luyt LG. Structure-activity study of ghrelin(1–8) resulting in high affinity fluorine-bearing ligands for the ghrelin receptor. J Med Chem. 2017;60(17):7256–66. https://doi.org/10.1021/ACS.JMEDCHEM.7B00164.CrossRefPubMed

165.

van den Berg NS, Buckle T, KleinJan GH, van der Poel HG, van Leeuwen FWB. Multispectral fluorescence imaging during robot-assisted laparoscopic sentinel node biopsy: a first step towards a fluorescence-based anatomic roadmap. Eur Urol. Elsevier; 2017;72(1):110–7. https://doi.org/10.1016/J.EURURO.2016.06.012.

166.

Hekman MCH, Rijpkema M, Langenhuijsen JF, Boerman OC, Oosterwijk E, Mulders PFA. Intraoperative imaging techniques to support complete tumor resection in partial nephrectomy. Eur Urol Focus. Elsevier B.V.; 2018;4(6):960–8. https://doi.org/10.1016/j.euf.2017.04.008.

167.

Bjurlin MA, McClintock TR, Stifelman MD. Near-infrared fluorescence imaging with intraoperative administration of indocyanine green for robotic partial nephrectomy. Curr Urol Rep. Current Medicine Group LLC 1; 2015;16(4):1–7. https://doi.org/10.1007/S11934-015-0495-9/METRICS.

168.

Penna FJ, Freilich DA, Alvarenga C, Nguyen HT. Improving lymph node yield in retroperitoneal lymph node dissection using fluorescent molecular imaging: a novel method of localizing lymph nodes in Guinea pig model. Urology. 2011;78(1):232.e15-232.e18. https://doi.org/10.1016/J.UROLOGY.2011.03.004.CrossRefPubMed

169.

Abdul-Muhsin HM, L’Esperance JO, Fischer K, Woods ME, Porter JR, Castle EP. Robot-assisted retroperitoneal lymph node dissection in testicular cancer. J Surg Oncol. John Wiley & Sons, Ltd; 2015;112(7):736–40. https://doi.org/10.1002/JSO.24018.

170.

Cheney SM, Andrews PE, Leibovich BC, Castle EP. Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int. John Wiley & Sons, Ltd; 2015;115(1):114–20. https://doi.org/10.1111/BJU.12804.

171.

Dogra PN, Singh P, Saini AK, Regmi Subodh K, Singh BG, Nayak B. Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor. Urol Ann. 2013;5(4):223–6. https://doi.org/10.4103/0974-7796.120289.CrossRefPubMedPubMedCentral

172.

de Cobelli O, Brescia A, Mazzoleni F, Musi G, Matei DV. A novel “intuitive” surgical technique for right robot-assisted retroperitoneal lymph node dissection for stage I testicular NSGCT. World J Urol 2012 31:3. Springer; 2012;31(3):435–9. https://doi.org/10.1007/S00345-012-1006-Y.

173.

Ercole CE, Mir MC, Autorino R, Kaouk JH. Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor. Urol Ann. 2014;6(1):99. https://doi.org/10.4103/0974-7796.127037.CrossRefPubMedPubMedCentral

174.••

Ge S, Zeng Z, Li Y, Gan L, Meng C, Li K, et al. The role of robotic retroperitoneal lymph node dissection in testicular cancer: a systematic review and meta-analysis. International Journal of Surgery. 2023; https://doi.org/10.1097/JS9.0000000000000520. This systematic review and meta-analysis compares the safety and efficacy of rRPLND in TC.

175.

Sigg S, Fankhauser CD. The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma. Curr Opin Urol. Wolters Kluwer Health; 2023;33(4):245. https://doi.org/10.1097/MOU.0000000000001099.

176.••

Hiester A, Che Y, Lusch A, Kuß O, Niegisch G, Lorch A, et al. Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol. 2023;84(1):25–31. DOI: https://doi.org/10.1016/J.EURURO.2022.10.021. This study, focusing on primary RPLND in patients with clinical stage IIA/B seminoma, explores the oncological efficacy and surgical safety of RPLND as an experimental treatment aiming to reduce toxicity associated with standard radiotherapy or chemotherapy.

177.

Heidenreich A, Paffenholz P, Nestler T, Pfister DA. Nerve sparing retroperitoneal lymph node dissection in clinical stage IIA/B seminoma: the COTRIMS trial. Am Soc Clin Oncol; 2022;40(6_suppl):418–418. https://doi.org/10.1200/JCO.2022.40.6_SUPPL.418.

178.

Cazzaniga W, Kinsella N, Reid A, Huddart R, Mayer E, Nicol D. Outcomes of minimally invasive retroperitoneal lymph node dissection (Primary MI- RPLND) followed by adjuvant carboplatin (AUC7) for clinical stage IIa/b seminoma. Eur Urol. Elsevier BV; 2023;83:S1065. https://doi.org/10.1016/S0302-2838(23)00794-7.

179.

Stout TE, Soni SD, Goh AC. Post-chemotherapy robotic bilateral retroperitoneal lymph node dissection using a novel single-dock technique. J Robot Surg. Springer London; 2016;10(4):353–6. https://doi.org/10.1007/S11701-016-0622-8/METRICS.

180.

Pooleri GK, Bijalwan P, Kesavan R, Philip A, Keechilat P. Robot-assisted supine extraperitoneal retroperitoneal lymph node dissection: a novel approach for template dissection in post-chemotherapy residual mass in non-seminomatous germ cell tumours. J Robot Surg. 2019;13(1):171–3. https://doi.org/10.1007/S11701-018-0810-9.CrossRefPubMed

181.

Syan-Bhanvadia S, Bazargani ST, Clifford TG, Cai J, Miranda G, Daneshmand S. Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity. Eur Urol. Elsevier; 2017;72(5):814–20. https://doi.org/10.1016/J.EURURO.2017.02.024.

182.

Kim P, Syan-Bhanvadia S, Djaladat H, Faber K, Tadros NN, Nichols C, et al. Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor. Urology. Elsevier; 2012;80(4):941–5. https://doi.org/10.1016/j.urology.2012.07.006.

At a glance: The STEP trials

Springer Medicine

Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2024

Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas

Integrated care in breast cancer

Novel therapeutic targets in AML

Update on the management of bone metastases

Head and Neck Mucosal Melanoma: Where Are We Now?

Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry

Keynote webinar | Spotlight on antibody–drug conjugates in cancer